Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
HARMONi-GI1
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
- NCT06591520 ↗
- Active, not recruiting
- Akeso
- Deep
We haven't built an HCP commentary report on HARMONi-GI1 (AK112 and durvalumab in Biliary Tract Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HARMONi-GI1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 76 | |
| YouTube | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Multi-center Phase III Study of AK112 Combined With Gemcitabine Plus Cisplatin Versus Durvalumab Combined With Gemcitabine Plus Cisplatin as the First-line Treatment for Patients With Advanced Biliary Tract Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- AK112, Gemcitabine, Cisplatin; Durvalumab, Gemcitabine, Cisplatin
- Arms
- AK112 + Gemcitabine + Cisplatin · Experimental
- Durvalumab + Gemcitabine + Cisplatin · Active comparator
- Enrollment
- 682
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Akeso
- Start
- Oct 20, 2024
- Primary completion
- Oct 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06591520 · updated Jan 21, 2026